Orion Pharma


Concise Prescribing Info
Diltiazem HCl
Angina pectoris, Prinzmetal's angina, HTN.
Dosage/Direction for Use
May be taken with or without food: Swallow whole, do not chew/crush.
Hypersensitivity. Cardiogenic shock, decompensated cardiac insufficiency, sick sinus syndrome or evidence of 2nd- or 3rd-degree AV block (w/o pacemaker), hypotension, severe bradycardia (<40 bpm), Wolff-Parkinson-White syndrome, acute complicated MI, left ventricular failure w/ pulmonary congestion, digitalis-intoxication. Concomitant use of dantrolene infusion. Pregnancy or lactation.
Special Precautions
Reduced left ventricular function, bradycardia or 1st-degree AV block, aortic stenosis; acute porphyria; mood changes eg, depression; risk of intestinal obstruction. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency, fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency. Concomitant use w/ β-blockers or other drugs impairing cardiac conduction or contractility; anaesth. May affect ability to drive & use machines. Renal or hepatic impairment. Not recommended in women of childbearing potential & during pregnancy. Not to be used during lactation. Elderly.
Adverse Reactions
Headache, dizziness, AV block, palpitations, peripheral oedema, flushing of face, nausea, constipation, dyspepsia, gastric pain, malaise, erythema, pruritus.
Drug Interactions
Lethal ventricular fibrillation w/ dantrolene infusion. Monitor lithium serum conc. Increased hypotensive effects, faintness w/ nitrate derivatives. Increased circulating theophylline, carbamazepine, cyclosporine levels. Increased antihypertensive effects w/ α-antagonists. Increased risk of bradycardia w/ amiodarone, digoxin. Possibility of rhythm disturbances, SA & AV conduction disturbances, heart failure w/ β-blockers. Additive risk of increased cardiac adverse effects w/ other antiarrhythmic agents. Decreased plasma levels w/ rifampicin, CYP3A4 inducers. Increased plasma conc w/ anti-H2 agents eg, ranitidine; strong CYP3A4 inhibitors, other CYP3A4 substrates eg, macrolide antibiotics, phenytoin, buspirone, nifedipine, sirolimus, tacrolimus, alfentanil, cisapride, HIV PIs. Increased cardiac depressant effect of halothane, isoflurane. Potential for additive effects w/ other agents affecting cardiac contractility &/or conduction. Potentiated effect w/ other antihypertensive agents. Increased plasma conc of midazolam, triazolam, alprazolam. Inhibition of methylprednisolone metabolism. Increased AUC of some statins eg, simvastatin, lovastatin, atorvastatin.
MIMS Class
Calcium Antagonists
ATC Classification
C08DB01 - diltiazem ; Belongs to the class of benzothiazepine derivative selective calcium-channel blockers with direct cardiac effects. Used in the treatment of cardiovascular diseases.
Cardil CR tab 120 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in